-
A second generation, selective, irreversible, monoamine oxidase type B inhibitor has been approved for the treatment of Parkinson's disease (PD).
-
There have been conflicting reports on the risks of ovarian cancer in users of hormone replacement therapy. In the NIH-AARP Diet and Health Study Cohort, analysis of various aspects of HRT and the development of ovarian cancer in approximately 100,000 women aged 50-71 years was undertaken.
-
Patients with transient ischemic attacks should usually be admitted to the hospital and receive rapid evaluation and treatment.
-
The Institute of Women's Health and Integrative Medicine is offering a seminar on Women's Cancers in Portland, OR, on Jan. 26-28.
-
Marcolina ST, Fenstemacher PA. Optimizing oral health in women: More than just lip service. Part 2 of a series on oral health. Altern Ther Women's Health 2007;9(1):1-7.
-
Brown D. Increased urinary lignan excretion association with decreased risk of uterine fibroids. Altern Ther Women's Health 2007;9(1):7-8.
-
There are a number of abnormalities apparent in the 12-lead ECG image. First, the rhythm is not sinus, as upright P waves are not seen in lead II.
-
The FDA has approved an oral, once-daily drug for the treatment of chronic hepatitis B. Telbivudine is the β-L enantiomer of thymidine with potent antiviral activity against hepatitis B virus.
-
A review of ambulatory medical malpractice cases of missed and delayed diagnoses reveals that they result from a witches' brew of multiple breakdowns, cognitive errors, and dysfunctional systems.
-
Annual CT scanning of at risk people can detect early (Stage 1) lung cancers and perhaps reduce the mortality rate of lung cancer in this group.